MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)

Abstract

Mucosal addressin cell adhesion molecule (MAdCAM-1) plays a pivotal role in T-lymphocyte homing to the gut. Given the strong association between the autoimmune liver diseases primary sclerosing cholangitis and autoimmune hepatitis and inflammatory bowel disease, we investigated the role of MAdCAM-1 in recruiting mucosal lymphocytes to the liver. MAdCAM-1 was strongly expressed on inflamed portal vein/sinusoidal endothelium in autoimmune mediated liver disease. In modified Stamper-Woodruff assays, MAdCAM-1 on hepatic vessels supported adhesion of ␣4␤7؉ lymphocytes (i.e., gut-derived T cells) from patients with inflammatory bowel disease and primary sclerosing cholangitis. This adhesion was inhibited by pretreatment with blocking antibodies to MAdCAM-1, ␣4␤7, or the integrin ␣4 chain indicating that MAdCAM-1 in inflamed liver is functionally active. Circulating lymphocytes from patients with primary sclerosing cholangitis showed rolling adhesion on MAdCAM-1 transfectants in a flow-based adhesion assay that could be blocked by anti-MAdCAM-1 or anti-␣4␤7 mAbs. These findings indicate that, under certain circumstances, vessels in the human liver support adhesion of ␣4␤7؉ mucosal lymphocytes via binding to aberrantly expressed MAdCAM-1 on liver endothelium. This provides a mechanism to explain the hepatic recruitment of mucosal lymphocytes in inflammatory liver disease complicating inflammatory bowel disease. (HEPATOLOGY 2001;33:1065-1072

Absence of β7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine

“…47 In addition, we found that cotransplantation of WT and ␤ 7 Ϫ/Ϫ donor T cells into the same recipient resulted in a far greater percentage of WT T cells infiltrating intestine. This experimental setup has the advantage of controlling for host expression of chemokines and circulating levels of inflammatory cytokines; both types of T cells are exposed to the same environment so that differences in infiltration may be assumed to be caused solely by the difference in T-cell integrin expression.…”

Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease

“…19 Similarly, endothelial expression of MAdCAM-1, previously thought to be restricted to the gastrointestinal tract, has recently been demonstrated on hepatic portal endothelium in inflammatory liver disease associated with IBD, including PSC. This hepatic endothelial MAdCAM-1 was shown to support a 4 b 7 mediated lymphocyte adhesion in vitro, 1 suggesting that it may have a functional role in lymphocyte recruitment.…”

“…Infiltrating lymphocytes in the extra-intestinal disorders of IBD are originally activated in the gut and then aberrantly recruited to extra-intestinal tissues. 1 Elucidating the mechanisms for lymphocyte homing to these tissues is therefore of great importance in advancing our understanding of the pathology of IBD.…”

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

“…Although vedolizumab is already approved for use in ulcerative colitis and Crohn's disease, a belief exists that its mechanism of action may confer efficacy for the treatment of primary sclerosing cholangitis, prompting the planning of a clinical trial to further investigate this supposition [107,108]. In addition to vedolizumab, simtuzumab is a novel humanized therapeutic antibody that targets the lysyl oxidase-like 2 (LOXL2) enzyme, the expression of which correlates with hepatic fibrosis.…”